Advanced basal cell carcinoma treated with vismodegib: impact on the lives of patients and their families.
Aged
Anilides
/ administration & dosage
Carcinoma, Basal Cell
/ drug therapy
Family
/ psychology
Female
Hedgehog Proteins
/ antagonists & inhibitors
Humans
Male
Middle Aged
Patients
/ psychology
Psychological Distress
Pyridines
/ administration & dosage
Quality of Life
Quinazolinones
/ administration & dosage
Skin Neoplasms
/ pathology
Surveys and Questionnaires
/ statistics & numerical data
Journal
Clinical and experimental dermatology
ISSN: 1365-2230
Titre abrégé: Clin Exp Dermatol
Pays: England
ID NLM: 7606847
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
accepted:
11
05
2020
pubmed:
18
5
2020
medline:
29
7
2021
entrez:
17
5
2020
Statut:
ppublish
Résumé
Locally advanced basal cell carcinoma (laBCC) represented an uncommon, difficult-to-treat form of skin cancer until the recent approval of the Hedgehog inhibitor vismodegib. Approximately 80% of laBCCs occur in the head and neck region, causing disfiguring skin changes that have an impact on patient quality of life (QoL). Because the lives of patients with advanced BCCs are severely disrupted, it would be expected that the QoL family members involved in caregiving would also be affected. The aim of our study was to quantify the QoL of both patients and family members during vismodegib treatment using the Dermatology Life Quality Index and the Family Dermatology Life Quality Index, respectively.
Substances chimiques
Anilides
0
Hedgehog Proteins
0
HhAntag691
0
Pyridines
0
Quinazolinones
0
ciliobrevin A
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1044-1046Informations de copyright
© 2020 British Association of Dermatologists.
Références
Mohan SV, Chang ALS. Advanced basal cell carcinoma: epidemiology and therapeutic innovations. Curr Dermatol Rep 2014; 3: 40-5.
Scalvenzi M, Costa C, Cappello M et al. Managing adverse effects by dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor vismodegib: a single-centre experience. J Eur Acad Dermatol Venereol 2019; 33: e145 -7.
Matthews BA, Rhee JS, Neuburg M et al. Development of the facial skin care index: a health-related outcomes index for skin cancer patients. Dermatol Surg 2006; 32: 924-34.
Basra MK, Finlay AY. The family impact of skin diseases: the Greater Patient concept. Br J Dermatol 2007; 156: 929-37.
Sampogna F, Finlay AY, Salek SS et al. European Academy of Dermatology and Venereology TaskForce on Quality of Life. Measuring the impact of dermatological conditions on family and caregivers: a review of dermatology-specific instruments. J Eur Acad Dermatol Venereol 2017; 31: 1429-39.
Gualdi G, Moro R, Regina V et al. PRISModegib: the use of the PRISM test to assess the health-related quality of life of patients with locally advanced basal cell carcinoma undergoing Hedgehog pathway inhibitor therapy. Br J Dermatol 2019; 81: 406-7.
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-16.
Finlay AY, Salek SS, Piguet V. Measuring family impact of skin diseases: FDLQI and FROM-16. Acta Derm Venereol 2015; 95: 1036.
Basra MK, Edmunds O, Salek MS, Finlay AY. Measurement of family impact of skin disease: further validation of the Family Dermatology Life Quality Index (FDLQI). J Eur Acad Dermatol Venereol 2008; 22: 813-21.
Villani A, Fabbrocini G, Cappello M et al. Real-life effectiveness of vismodegib in patients with metastatic and advanced basal cell carcinoma: characterization of adverse events and assessment of health-related quality of life using the Dermatology Life Quality Index (DLQI) test. Dermatol Ther (Heidelb) 2019; 9: 505-10.